ArticleEuropean journal of cancer (Oxford, England : 1990)2025

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

Philipp Jansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.